This could create a vicious cycle that exaggerates the activation of Nrf2 and inhibition of NF-κB, which ultimately prevents oxidative and inflammatory damage to the hepatocytes and alleviates hepatic steatosis. Here, NFKB1 is linked to fatty liver disease.